InvestSMART

INOVIQ Ltd (ASX:IIQ)

ALERT: Price-sensitive ASX Announcement for IIQ
Current share price for IIQ : $0.210 -0.335 (-61.47%)+
Announcement
Release
1 Jul 2026 9:10AM
Price at Release
$0.545
Full Release
download
Summary
INOVIQ Ltd has been developing the EXO-OC™ test, an exosome-based blood test for ovarian cancer detection using its proprietary EXO-NET® technology. The test is designed to identify ovarian cancer early, aiming to improve detection accuracy. Initial studies showed promising sensitivity and specificity, but further testing encountered challenges with sample quality, impacting study outcomes. Nonetheless, INOVIQ remains committed to enhancing the test and plans to commercialize it as a Laboratory Developed Test in the US. The EXO-OC™ test has a provisional patent application filed, reinforcing its proprietary status.
Key Points
  • INOVIQ's EXO-OC™ test is an exosome-based blood test for early detection of ovarian cancer.
  • The EXO-OC™ test uses INOVIQ’s EXO-NET® technology and AI/ML algorithms.
  • Initial trials showed 100% sensitivity for stage I/II and 77% sensitivity for all stages at 99.6% specificity.
  • Updated algorithm achieved 92.3% sensitivity for stage I/II and 92.5% for all stages at 98% specificity.
  • Expanded study faced issues with sample quality, affecting data analysis.
  • INOVIQ plans to commercialize EXO-OC™ as a Laboratory Developed Test in the US.
  • A provisional patent application for the EXO-OC™ test has been filed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.